Data / Drug companies / Guaifenesin and pseudoephedrine hcl
Guaifenesin and pseudoephedrine hcl: 14 companies and 23 products in the FDA NDC directory
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Guaifenesin and pseudoephedrine hcl is listed in the FDA National Drug Code Directory by 14 companies, with 23 products in commercial distribution. 22 of the products (95.7%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are tablet, extended release; tablet, and the newest product started marketing on October 12, 2026.
The request: Get every company that lists guaifenesin and pseudoephedrine hcl in the FDA NDC directory, with headquarters, website and number of employees. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 14
- Products
- 23
- Generic (ANDA) products
- 22 (95.7%)
- Application numbers
- 5
- Routes
- Oral
- Brand names
- Mucus Relief D, Poly-Vent Ir
- openFDA record search
- api.fda.gov
Companies that list guaifenesin and pseudoephedrine hcl
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Walgreen Company | 4 | tablet, extended release | Generic drugs (ANDA) | May 7, 2022 |
| Aurohealth LLC | 2 | tablet, extended release | Generic drugs (ANDA) | March 25, 2020 |
| Dr. Reddy's Laboratories Limited | 2 | tablet, extended release | Generic drugs (ANDA) | December 29, 2017 |
| Granules India Limited | 2 | tablet, extended release | Generic drugs (ANDA) | June 1, 2023 |
| Ohm Laboratories Inc. | 2 | tablet, extended release | Generic drugs (ANDA) | April 1, 2021 |
| Rite Aid Corporation | 2 | tablet, extended release | Generic drugs (ANDA) | February 1, 2022 |
| Strategic Sourcing Services LLC | 2 | tablet, extended release | Generic drugs (ANDA) | December 13, 2024 |
| Amerisource Bergen | 1 | tablet, extended release | Generic drugs (ANDA) | October 1, 2024 |
| CVS Pharmacy | 1 | tablet, extended release | Generic drugs (ANDA) | July 8, 2019 |
| Kroger Company | 1 | tablet, extended release | Generic drugs (ANDA) | April 16, 2021 |
| Meijer, Inc. | 1 | tablet, extended release | Generic drugs (ANDA) | July 15, 2021 |
| Poly Pharmaceuticals, Inc. | 1 | tablet | Over the counter monograph drugs | June 11, 2013 |
| Rugby Laboratories | 1 | tablet, extended release | Generic drugs (ANDA) | October 12, 2026 |
| Wal-Mart Stores Inc | 1 | tablet, extended release | Generic drugs (ANDA) | April 3, 2020 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, extended release | 22 | 95.7% |
| Tablet | 1 | 4.3% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 22 | 95.7% |
| Over the counter monograph drugs | 1 | 4.3% |
Pharmacologic classes
| Class | Products |
|---|---|
| Expectorant | 23 |
| alpha-Adrenergic Agonist | 23 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.